News & Events
Join Us at Upcoming Events
|May 28, 2017||May 29, 2017||May 30, 2017||May 31, 2017||June 1, 2017||June 2, 2017||June 3, 2017|
|June 4, 2017||June 5, 2017||June 6, 2017||June 7, 2017||June 8, 2017||June 9, 2017||June 10, 2017|
|June 11, 2017||June 12, 2017||June 13, 2017||June 14, 2017||June 15, 2017||June 16, 2017||June 17, 2017|
|June 18, 2017||June 19, 2017||June 20, 2017||June 21, 2017||June 22, 2017||June 23, 2017||June 24, 2017|
|June 25, 2017||June 26, 2017||June 27, 2017||June 28, 2017||June 29, 2017||June 30, 2017||July 1, 2017|
25-28 April 2017
Charing Cross Symposium
London, United Kingdom
29 Jun – 1 Jul 2017
European Venous Forum
16-20 Sep 2017
19-22 Sep 2017
ESVS 31st Annual Meeting
26-28 Oct 2017
EVF How 2017
14-17 Nov 2017
New York, NY
08 Sept 2016 – VENITI® Closes on $25M from Boston Scientific
VENITI, Inc., a leader in the advancement of treatment for deep venous disease, has closed on $25 million in Series D equity financing from Boston
20 June 2016 – VENITI® Announces 1,000TH Patient Treated With VICI VENOUS STENT®
Venous stent designed specifically for the challenges of the venous system achieves adoption milestone
13-14 May 2016 – VENITI®’s will present on Venous Stents at the ESVS Spring Meeting in London, UK
– Venous Stents – Design Optimization for the Clinical Challenge- Vice President of Research and Development, Stephen Kao
26-29 April 2016 – VENITI® will present the VIRTUS Trial Update at Charing Cross in London, UK
– VIRTUS Trial Update – Lowell S. Kabnick, MD, RPhS, NYU Langone MC, New York, NY
22 April 2016 – VENITI® Completes First Use Of VICI VERTO VENOUS STENT™, Novel Venous Stent System
17-21 November 2015 – VENITI® will attend the 2015 VEITH symposium in New York, NY
3:46pm – 3:51 pm Tuesday, 17 November 2015 – Early Experience With The VENITI VICI VENOUS STENT And Update On The VIRTUS Trial, William Marston, MD, University of NC, Chapel Hill, NC
10:05am – 10:10am Thursday, 19 November 2015 – VIRTUS: An Evaluation of the VICI VENOUS STENT System In Patients with Chronic Iliofemoral Venous Outflow Obstruction, Mikel Sadek, MD, NYU Langone MC, New York, NY
10:29am – 10:34am Thursday, 19 November 2015 – Luncheon Symposium – Comprehensive Review of Venous Outflow Obstruction: Diagnosis, Care Pathway and Treatment
12pm – 1pm Friday, 20 November 2015 – What is the Ideal Venous Stent, Lowell Kabnick, MD, NYU Langone MC, New York, NY
10 March 2015 – VENITI®, Inc. Announces Closing of Equity and Debt Funding
9 February 2015 – Frost & Sullivan Applauds VENITI’s Dedication to Improving the Treatment of Chronic Venous Diseases (CVD) through Unique and Differentiated Products
11 January 2015 – First Patients Treated in Germany with VENITI® VICI VENOUS STENT System ®
5 January 2015 – The VIRTUS Trial for the VENITI® VICI Venous Stent System
Percutaneous stenting of the iliofemoral venous outflow system has evolved in to the preferred approach for management of chronic venous obstruction. The procedure can be performed with low morbidity, low mortality, long-term high patency rate, and low rate of in-stent restenosis.
1 December 2014 – VENITI®, Inc. Announces First U.S. Patients Enrolled in VIRTUS Trial
VENITI, Inc., a company dedicated to advancing the treatment of venous disease, announced that it has enrolled the first United States patients in the VIRTUS trial of the VENITI VICI™ Venous Stent System. The four procedures were performed at two sites, including the Heart and Vascular Center, St. Joseph Hospital, Orange, CA.
14 July 2014 – VENITI®, Inc. Announces FDA Approval of IDE for VENITI VICI™ Venous Stent System, First Patients Enrolled in VIRTUS Trial
VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System.
23 January 2014 – VENITI®, Inc. Announces First Uses of Veniti Vici Venous Stent System
VENITI announced today that patients in the European Union (EU) were successfully treated for symptomatic venous outflow obstruction of the lower extremities with the Veniti Vici™ Venous Stent System. These procedures mark the first uses in patients of this novel Venous Stent from VENITI.
6 November 2013 – VENITI® Receives CE Mark Approval for Vici Venous Stent
Veniti Inc. has received approval to CE Mark the Veniti Vici™ Venous Stent, specifically designed for the treatment of adult patients who exhibit systematic venous outflow obstruction. The CE Mark allows Veniti to sell products within the European Union.
We are eager to answer them. Call us directly or submit the convenient online form below.